Windlas Biotech Limited - IPO details

The company was incorporated as 'Windlas Biotech Limited' on February 19, 2001. The Company is one of the leading in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage form and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubilify. Windlas Biotech provides a comprehensive range of  CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics.

Market Share:- In 2020 Windlas Biotech Limited's market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry.

Sales Process:- The company also sell their own branded products in the trade generics and OTC market as well as export generic products to several countries.  

Current Focus:- Windlas Biotech Limited currently focus on launching new complex generic products in chronic therapeutic category linked in to lifestyle related disorders.

Business Verticals:- The Company has three distinct strategic business verticals.

1. CDMO Service and Products
2. Domestic Trade Generics and over-the-counter Brands
3. Exports

All verticals are supported by a network of R&D laboratories and manufacturing facilities which in turn are supported by various functions, including supply chain, inventory, finance and human resources.

Company Strengths:-

1. Leading CDMO in India with a focus on the chronic therapeutic category.
2. Innovative Portfolio of complex generic products supported by robust R&D Capabilities.
3. Efficient and quality compliant manufacturing facilities with significant entry barriers.
4. Strong and long-term relationships with leading Indian pharmaceutical Companies
5. Consistent track record of financial performance
6. Experienced Professional and Technical Qualified Management Team

Financial Reports:-

Particulars	Years (amt in Millions)
	31-12-2020	31-03-2020	31-03-2019
Total Assets	3158.83	3384.88	2981.80
Total Revenue	3230.94	3313.39	3565.76
Profit After Tax	96.74	162.13	638.22

 

IPO Details:-

IPO Opening Date	4/08/2021
IPO Closing Date	06/08/2021
Face Value	5 Rs. Per Equity Share
IPO Price	Rs. 448 to Rs.460 per Share
Market Lot	30 Shares
Listing At	BSE, NSE
Issue Size	401.54 Cr

IPO Table:-

IPO Open Date	04/08/2021
IPO Close Date	06/08/2021
Allotment Date	11/08/2021
Listing Date	17/08/2021

  

IPO Lot Size:-

minimum 1 lot (30 shares, amt 13800 Rs.) maximum 14 lots (420 Shares, amt 193200Rs.)

Our Suggestion 

Recommended for short term

Rolex Rolled Rings IPO Details with Grey Market Premium.

 Company History:-

Rolex Rolled Rings started as a partnership in 1977-78 under the name Rolex Industries, and was later converted into a joint stock company under the Companies Act 1951, with the name Rolex Rings Pvt Ltd and a certificate of incorporation dated February 13, 2003.

Business Overview:-

The company produces hot rolled forged and machine bearing rings, as well as automotive components for vehicle segments such as two-wheelers, passenger vehicles, commercial vehicles, off-highway vehicles, electric vehicles, industrial machines, wind turbines, and railways. The Company domestically and internationally to large marquee customers, including some leading bearing manufacturing companies. The Company has 22 forging lines with a combined installed capacity of 1,44,750 M.T.P.A., Machining facility with 528 spindles and a total install capacity of 69 million components per year.

Company Strength:-

1. One of the Top 5 Forging Company.
2. Strong Manufacturing Capacity
3. Good business background History.
4. Export in 19 Countries since long time with healthy relation
5. Continue financial growth

Financial Details of Company:-

Particulars	Years     (amt in a million)
	31-03-2021	31-03-2020	31-03-2019
Total Assets	7969.24	6861.73	7822.57
Total Revenue	6197.57	6753.32	9112.54
Profit After Tax	869.55	529.41	590.51

 IPO Details:-                                                                  

IPO Opening Date	28-07-2021
IPO Closing Date	30-07-2021
Face Value	10 Rs. Per Equity Share
IPO Price	880 Rs. To 990 Rs.
Market Lot	16 Shares
Listing At	BSE, NSE
Issue Size	731 CR.

IPO Time Table:-

IPO Open Date	28-07-2021
IPO Close Date	30-07-2021
Allotment Date	04-08-2021
Listing Date	09-08-2021

IPO Lot Size:

minimum lot size 1 (16 shares =14400Rs.) & maximum lot size 13 (208 shares = 187200Rs.)

Grey Market Premium:-

Grey market premium as on 27-07-2021 is 450 Rs. per share.

Our Suggestion:-

Recommended.

IPO: Glenmark Life Sciences.

COMPANY HISTORY

Glenmark Life Sciences (GLS) is founded in 2011. The company is a leading developer and manufacturer of Active Pharmaceutical Ingredients. GLS partners with the world's 16 of the top 20 generic companies & serves customers in multiple geographies including North America, Europe, Japan, Latin America and ROW.

Financials of The Company

Particulars	Years (amt in lakh)
	31/03/2021	31/03/2020	31/03/2019
Total Assets	19970.75	17256.04	14753.95
Total Revenue	18859.76	15493.03	8868.65
Profit After Tax	3515.81	3130.98	1955.92

Promoters' Holding:

After successful listing, promotors' Holding will be reduced form 100% to 82.84%.

IPO Details

IPO Opening Date	27-07-2021
IPO Closing Date	29-07-2021
IPO PRICE	Rs.695 to Rs.720 per equity share
Minimum Lot Size	20 Shares (1Lot)
Maximum Lot Size	260 Shares (13Lots)
Minimum Investment Amount	14400
Maximum Investment Amount	187200
Listing At	BSE, NSE
Issue Size	Equity Shares of Rs.2 (aggregating up to Rs.1513.6 Cr)
IPO Listing Date	06-08-2021

Grey Market Premium

GLS IPO grey market premium today is Rs.210.

My Recommendation

Every one should apply for this IPO.

NFO:- NIPPON INDIA FLEXI CAP FUND

           

Nippon India Flexi Cap Fund is an open-ended dynamic equity scheme investing across large cap, medium cap, and small cap stocks.

Fund suitable for whom?

 This fund is suitable for those who are looking for Long term capital growth.

Fund Size?

Rs.1.76 Trillion

Benchmark Index?

Fund will be benchmarked under Nifty500 TRI.

Fund Managers?

·            Manish Gunwani, Dhrumil Shah

·         Varun Goenka & Nikhil Rungta (Co Fund Managers)

·         Kajal Desai (dedicated Fund Manager for Overseas Fund)

Time duration for Investment

Opens form	Close on	Reopen for continuous sales and repurchase not later than
July 26, 2021	August 09, 2021	August 24, 2021

Investment Objective:-

The primary objective of the scheme is to seek to generate appreciation & provide long-term growth opportunities by investing in a portfolio constituted of equity securities & equity related securities. The second objective is to generate consistent returns by investing in debt and money market securities.

Asset Allocation Pattern of the fund

Instruments	Indicative asset allocation (%)		Risk Profile
	Minimum	Maximum	Low/Medium/High
Equity & Equity related instruments	65%	100%	Medium to High
Debt & Money Market Instruments	0%	35%	Low to Medium

An overall limit of 50% of the portfolio value has been introduced for the purpose of equity derivatives in the scheme.

The scheme may intend to invest up to US $150 million in ADR/GDR/Foreign Securities/Overseas ETFs in the six months of post closer of NFO.

Conclusion:

Invest in this fund for long term.

MUTUAL FUND- A NEW AGE WEALTH CREATOR

MUTUAL FUND- A NEW AGE WEALTH CREATOR

Mutual funds have shown to be the most effective asset for accumulating wealth. Due to the expansion of the Indian market and foreign investment, India is now on the verge of becoming a commercial hub as a result of the corona effect. Following Corona, all foreign investors and businesses are relocating their production facilities from China to India. According to the report, the Indian economy is recovering faster than other developed economies.

In compared to bank fixed deposits and other saving plans, mutual funds provide excellent returns to investors. All mutual fund companies gave returns ranging from 25% to 100% in 2020-2021. If someone invested Rs. 1,000,000 in March 2020, their gains would be nearly doubled now.

In reality, SEBI has raised the offshore investment ceiling for mutual fund companies from USD 600 million to USD 1 billion, with the total mutual fund sector limited at USD 7 billion. The increased ceiling would allow mutual funds to devote a larger portion of their assets to overseas securities. Following that, a slew of new NFOs (New Fund Openings) were launched, and mutual fund firms shifted their focus to global funds. This has a significant influence on investors as well.

Banks' fixed deposit rates, on the other hand, are steadily declining. According to a poll conducted last year, consumers should withdraw their assets from the bank and put them in a mutual fund. Yes, investing in mutual funds carries some risk, but as the famous dialogue from the web series Scam goes, "Risk hai to ishq hai," people choose to accept risks in exchange for better returns.

Finally, people are smart enough to capitalize their risk factors, and in the digital world, all results and investment details of any company are available in a single click, and anyone can invest in a fund by comparing results, so it can be concluded that mutual funds are the New Age Wealth Creator today in a real way.